Back to search

Article

The FLT3 tyrosine kinase receptor ITD mutation controls its expression and drug resistance in acute myeloid leukaemia

2021-01-01

Abstract excerpt

In approximately 23% of AML patients, Fms-like tyrosine kinase 3 (FLT3) contains a gain-of-function, internal tandem duplication (ITD) mutation that is associated with an unfavourable prognosis. FLT3 is therefore seen as a promising therapeutic avenue for AML and as a result, a more complete understanding of its function and signalling may lead to additional targets and resistance mechanisms being identified. To d...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
95bb4b28-1f09-567a-8e50-08774c86ad42
DOI
10.17638/03115507
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
The FLT3 tyrosine kinase receptor ITD mutation controls its expression and drug resistance in acute myeloid leukaemiaDOI 10.17638/03115507
FLT3-ITD and its current role in acute myeloid leukaemia.Semantic proximity
Targeting FLT3 mutations in AML: review of current knowledge and evidenceSemantic proximity
FLT3 inhibitors in the treatment of acute myeloid leukemia: current status and future perspectives.Semantic proximity
Advances in the pathogenesis of FLT3 -mutated acute myeloid leukemia and targeted treatments.Semantic proximity
Pharmacological impact of FLT3 mutations on receptor activity and responsiveness to tyrosine kinase inhibitors.Semantic proximity
The Future of Targeting FLT3 Activation in AML.Semantic proximity
The role of quizartinib in the treatment of acute myeloid leukemia.Semantic proximity
Tyrosine kinase inhibitors targeting FLT3 in the treatment of acute myeloid leukemiaSemantic proximity
Quizartinib: a potent and selective FLT3 inhibitor for the treatment of patients with FLT3-ITD-positive AML.Semantic proximity
“FLipping” the Story: FLT3-Mutated Acute Myeloid Leukemia and the Evolving Role of FLT3 InhibitorsSemantic proximity
Targeting FLT-3 Mutations in Acute Myeloid Leukaemia: from Molecular Insights to Clinical Strategies.Semantic proximity
FLT3 inhibitors and novel therapeutic strategies to reverse AML resistance: An updated comprehensive review.Semantic proximity
Select a neighboring publication to make it the new centre.